Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis

Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design

(2012) V. S. Terra et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Exploiting the Campylobacter jejuni protein glycosylation system for glycoengineering vaccines and diagnostic tools directed against brucellosis

(2012) Jeremy A Iwashkiw et al.   Microbial Cell Factories

Prevnar 13, the New 13-Valent Pneumococcal Conjugate Vaccine

(2011) Allana J Sucher et al.   ANNALS OF PHARMACOTHERAPY

Francisella tularensis: A Red-blooded Pathogen

(2011) J. W. Conlan   JOURNAL OF INFECTIOUS DISEASES

Genetic Modification of the O-Polysaccharide of Francisella tularensis Results in an Avirulent Live Attenuated Vaccine

(2011) Tae-Hyun Kim et al.   JOURNAL OF INFECTIOUS DISEASES

Production of glycoprotein vaccines in Escherichia coli

(2010) Julian Ihssen et al.   Microbial Cell Factories

N-linked glycosylation in bacteria: an unexpected application

(2009) Rebecca H Langdon et al.   Future Microbiology

Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge

(2009) L. E. Cole et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis

(2008) Shite Sebastian et al.   VACCINE

Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS)

(2007) J.E. Eyles et al.   MICROBIAL PATHOGENESIS